168 related articles for article (PubMed ID: 33841154)
1. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.
Cui H; Wang Q; Miller DD; Li W
Front Pharmacol; 2021; 12():637098. PubMed ID: 33841154
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2.
Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H
Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318
[TBL] [Abstract][Full Text] [Related]
3. MitoCur-1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14.
Li G; Zhou C; Wang L; Zheng Y; Zhou B; Li G; Ma Z; Sun P; Deng Y; Su L; Wang J; Cui H
Pigment Cell Melanoma Res; 2024 Mar; 37(2):316-328. PubMed ID: 37985430
[TBL] [Abstract][Full Text] [Related]
4. Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis
Wang L; Otkur W; Wang A; Wang W; Lyu Y; Fang L; Shan X; Song M; Feng Y; Zhao Y; Piao HL; Qi H; Liu JW
Front Pharmacol; 2022; 13():906043. PubMed ID: 36034784
[TBL] [Abstract][Full Text] [Related]
5. Silencing FOXP2 reverses vemurafenib resistance in BRAF
Jiang S; Huang Y; Li Y; Gu Q; Jiang C; Tao X; Sun J
Endocrine; 2023 Jan; 79(1):86-97. PubMed ID: 36331719
[TBL] [Abstract][Full Text] [Related]
6. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
7. Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Kawaguchi K; Igarashi K; Murakami T; Zhao M; Zhang Y; Chmielowski B; Kiyuna T; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Aug; 118(8):2314-2319. PubMed ID: 28106277
[TBL] [Abstract][Full Text] [Related]
8. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis.
Tang F; Li S; Liu D; Chen J; Han C
Transl Cancer Res; 2020 Mar; 9(3):1584-1593. PubMed ID: 35117506
[TBL] [Abstract][Full Text] [Related]
10. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
11. Silencing
Liu C; He S; Zhang J; Li S; Chen J; Han C
Onco Targets Ther; 2020; 13():4905-4915. PubMed ID: 32581551
[TBL] [Abstract][Full Text] [Related]
12. Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy
Li H; Wang Y; Su R; Jia Y; Lai X; Su H; Fan Y; Wang Y; Xing W; Qin J
Front Oncol; 2022; 12():794216. PubMed ID: 35141161
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
14. Role of Rho/MRTF in Aggressive Vemurafenib-Resistant Murine Melanomas and Immune Checkpoint Upregulation.
Foda BM; Neubig RR
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762086
[TBL] [Abstract][Full Text] [Related]
15. A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.
Feng JH; Nakagawa-Goto K; Lee KH; Shyur LF
Mol Cancer Ther; 2016 Jun; 15(6):1163-76. PubMed ID: 27048951
[TBL] [Abstract][Full Text] [Related]
16.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
17. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
19. BRAF
Feng L; Li J; Bu X; Zuo Y; Shen L; Qu X
Biochem Biophys Res Commun; 2020 Mar; 524(1):28-35. PubMed ID: 31980175
[TBL] [Abstract][Full Text] [Related]
20. Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Zhao M; Zhang Y; Nelson SD; Russell TA; Dry SM; Singh AS; Chmielowski B; Li Y; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jul; 16(13):1288-1294. PubMed ID: 28622068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]